Cargando...
Bioactive nanotherapeutic trends to combat triple negative breast cancer
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achiev...
Guardado en:
| Publicado en: | Bioact Mater |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
KeAi Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970221/ https://ncbi.nlm.nih.gov/pubmed/33778204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bioactmat.2021.02.037 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|